

Article

Increased insulin resistance in men with unexplained infertility



Ragaa Mansour^{a,*}, Yahia El-Faissal^{a,b}, Ahmed Kamel^{a,b}, Omnia Kamal^a, Gamal Aboulserour^a, Mohamed Aboulghar^{a,b}, Ibrahim Fahmy^{a,c}

^a The Egyptian IVF-ET Centre, 11431 Cairo, Egypt

^b Faculty of Medicine, Obstetrics and Gynecology Department, Cairo University, 11559 Cairo, Egypt

^c Faculty of Medicine, Andrology Department, Cairo University, 11559 Cairo, Egypt



Ragaa Mansour graduated from medical college with honours in 1973, obtaining her MSc in Obstetrics and Gynaecology from Cairo University in 1978. She is the founder and director of the Egyptian IVF Center.

KEY MESSAGE

Insulin resistance in men with unexplained infertility may be a cause of reproductive and metabolic abnormalities. The benefit of insulin-sensitizing agents for these patients should be tested.

ABSTRACT

This prospective case-control study aimed to test the presence of insulin resistance (IR) in men with unexplained infertility. We included two groups: the study group including 160 infertile men with unexplained oligozoospermia (sperm count $<10 \times 10^6/\text{ml}$) and normal hormonal profile, and the control group of 79 men with proven fertility within the preceding year. A fasting blood test measured IR, FSH, LH, total cholesterol, low-density lipoprotein, high-density lipoprotein and triglycerides. Insulin level was significantly higher in the study group (13.67 ± 10.44) compared with the control group (5.46 ± 3.15), $P < 0.0001$, and IR was significantly higher in the study group, $P < 0.0001$. FSH was significantly ($P < 0.0001$) higher in the study group (4.71 ± 2.57) than the control group (3.15 ± 1.92). LH was significantly higher in the study group (4.98 ± 2.41) compared with the control group (3.15 ± 1.12), $P < 0.0001$. Total cholesterol was significantly higher in the study group (198.29 ± 37.52) than the control group (182.45 ± 35.92), $P < 0.05$. In conclusion, IR in men with unexplained infertility may be a cause of reproductive and metabolic abnormalities. The benefit of insulin-sensitizing agents for these patients should be tested.

© 2017 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: ragaa.mansour@gmail.com (R Mansour).

<https://doi.org/10.1016/j.rbmo.2017.08.020>

1472-6483/© 2017 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Insulin resistance (IR) has been considered a major contributor to the pathogenesis of chronic oligoovulation or anovulation as well as other metabolic abnormalities in women with polycystic ovary syndrome (PCOS) [Diamanti-Kandarakis and Dunaif, 2012; Rosenfield, 1997]. The genetic contribution of PCOS has been mapped reproducibly by several investigators [Day et al., 2015; Goodarzi et al., 2012; Hayes et al., 2015; Legro et al., 1998; Shi et al., 2012]. Interestingly, similar reproductive and metabolic phenotype characteristics were found in first-degree male relatives to PCOS females [Legro et al., 2002; Liu et al., 2014; Recabarren et al., 2008a, 2008b]. It seems that PCOS is a complex trait because of the interaction of genetic and environmental factors [Rosenfield and Ehrmann, 2016].

Unexplained or idiopathic male factor infertility means no aetiological factor could be found using the common clinical, instrumental or laboratory methods [Cavallini, 2006]. It was considered that about 60–75% of male infertility cases are idiopathic, because the molecular mechanisms underlying the defects remain unknown [Filliponi and Feil, 2009]. Testicular histopathology of those patients shows various degrees of spermatogenic impairment but fail to identify specific pathogenesis [Nieschlag and Kamischke, 2010].

Our hypothesis is that some cases of unexplained male infertility could be due to IR, leading to hypogonadism and other metabolic features [Mansour et al., 2013]. The aim of this work was to test the presence of IR in men with unexplained infertility.

Materials and methods

Study population

One hundred and sixty men with idiopathic oligozoospermia participated in this study. The diagnosis of unexplained infertility was established after complete clinical and laboratory examination of the patients by our andrologists. At least two semen analyses 1–4 weeks apart were evaluated [WHO, 2010]. The inclusion criteria were infertile men with sperm count less than $10 \times 10^6/\text{ml}$; men with normal hormonal profile (FSH = 1–10 mIU/ml and LH = 1.8–12 mIU/ml), normal secondary sexual characters, and normal sexual function were included. Cases with chronic debilitating illness (e.g. cardiac diseases, epilepsy, renal disorders), diabetes mellitus, clinically evident varicocele, persistent pyospermia, abnormal karyotype, and azoospermia factor microdeletion were excluded. The control group included 79 men with proven fertility within the preceding year.

Methods

Fasting blood samples from the study and control groups were taken to measure the following: serum insulin, glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), testosterone, FSH, LH and prolactin.

IR was calculated by inverting the value of insulin sensitivity. Insulin sensitivity was calculated using the quantitative insulin sensitivity check index (QUICKI). It was derived using the inverse of the sum of the logarithms of the fasting insulin and fasting glucose: $1/(\log(\text{fasting insulin mIU/l}) + \log(\text{fasting glucose mg/dl}))$. This index correlates well with

glucose clamp studies ($r = 0.78$), and is useful for measuring insulin sensitivity. It is the preferred method for certain types of clinical research [Katz et al., 2000].

Another method to calculate IR is the homeostatic model assessment (HOMA) test [Matthews et al., 1985]. This is calculated by dividing by 405 the result of multiplying fasting serum insulin by fasting blood glucose, i.e. $[\text{fasting glucose (mg/dl)} \times \text{fasting insulin (mIU/l)}]/405$.

Body weight, height and body mass index (BMI) were measured and calculated.

Clinical trial registration number: NCT 01509482 at clinical trials.gov.

Ethical approval

The Internal Review Board and Ethical Committee of The Egyptian IVF-ET Centre approved the study on 1 January 2012 (reference number 2012–1).

Statistical analysis

Statistical Package for the Social Sciences (SPSS) version 15 (SPSS Inc., USA) was used. The Mann-Whitney test was used to compare quantitative variables that were not normally distributed. Student's *t*-test was used to compare quantitative variables that were normally distributed. $P < 0.05$ was considered statistically significant. The sample sizes were calculated using the OpenEpi sample size calculator for unmatched case control studies. We assumed a confidence level of 95%, an 80% power, a 5% hypothetical proportion of controls with exposure and a 95% hypothetical proportion of cases with exposure (<http://www.openepi.com/SampleSize/SSCC.htm>).

Results

Fasting insulin level was significantly higher in the study group (13.67 ± 10.44 mIU/l) compared with the control group (5.46 ± 3.15 mIU/l), $P < 0.0001$. Fasting glucose was 95.86 ± 25.22 mg/dl in the study group, compared with 94.41 ± 30.40 mg/dl in the control group, with no significant difference. Using QUICKI, IR was higher in the study group (2.99 ± 0.33) compared with the comparator group (2.61 ± 0.33), $P < 0.0001$. Using HOMA, IR was higher in the study group (3.07 ± 2.81) compared with the control group (1.25 ± 0.75), $P < 0.0001$ (Table 1). Triglycerides were higher in the study group (142.82 ± 105.31 mg/dl) as compared with the comparator group (114.59 ± 61.42 mg/dl), but not significantly different. Total cholesterol was higher in the study group (198.29 ± 37.52 mg/dl) than in the control group (182.45 ± 35.92 mg/dl), $P < 0.05$. HDL and LDL levels were comparable in both groups with no statistical significance (Table 1). FSH levels were higher in the study group (4.71 ± 2.57 mIU/ml) as compared with the control group (3.15 ± 1.92 mIU/ml), $P < 0.0001$. LH values were higher in the study group (4.98 ± 2.41 mIU/ml) as compared with the controls (3.15 ± 1.12 mIU/ml), $P < 0.0001$. Testosterone levels were found to be lower in the study group (5.35 ± 3.02 ng/ml) as compared with the control group (6.62 ± 3.51 mIU/ml), with $P < 0.001$ (Table 1). The BMI was 29.79 ± 3.21 in the study group and 29.12 ± 3.75 in the control group. The mean age was not significantly different between the two groups (Table 1).

Table 1 – Participants' characteristics and study results.

	Study group (n = 160)	Control group (n = 79)	Reference ranges	P-value
Age (years)	35.12 ± 6.15	34.51 ± 5.61	–	NS
BMI	29.79 ± 3.21	29.12 ± 3.75	–	NS
Fasting serum insulin (mIU/ml)	13.67 ± 10.44	5.46 ± 3.15	0–25	<0.0001
Fasting blood glucose (mg/dl)	95.86 ± 25.22	94.41 ± 30.40	65–105	NS
Insulin resistance (inverse QUICKI)	2.99 ± 0.33	2.61 ± 0.33	–	<0.0001
Insulin resistance (HOMA)	3.07 ± 2.81	1.25 ± 0.75	–	<0.0001
Total cholesterol(mg/dl)	198.29 ± 37.52	182.45 ± 35.92	116–212	<0.05
Triglycerides(mg/dl)	142.82 ± 105.31	114.59 ± 61.42	50–150	NS
High-density lipoproteins (mg/dl)	43.15 ± 10.62	43.65 ± 15.02	40–80	NS
Low-density lipoproteins (mg/dl)	139.52 ± 106.54	140.74 ± 138.43	85–125	NS
FSH (mIU/ml)	4.71 ± 2.57	3.15 ± 1.92	1–10	<0.0001
LH (mIU/ml)	4.98 ± 2.41	3.15 ± 1.12	1.8–12	<0.0001
Prolactin (ng/ml)	12.82 ± 6.95	12.01 ± 7.96	3–15	NS
Total testosterone (ng/ml)	5.35 ± 3.02	6.62 ± 3.51	2.49–8.36	<0.001

Values presented as mean ± SD.

BMI = body mass index; NS = not statistically significant.

Discussion

This study identified a group of idiopathic infertile men with IR and other metabolic findings similar to features of PCOS. The link between IR and male infertility has not been clearly demonstrated in the literature. It was suggested that insulin-like growth factor-1 (IGF-1) and its derangement may be involved in male infertility associated with low sperm count [Colombo and Naz, 1999]. In the meantime, IR is directly associated with IGF-1 levels [Friedrich et al., 2012; Sesti et al., 2005]. However, an inverse correlation between IR and male reproductive functions could not be found [Verit et al., 2014]. It has been demonstrated that parents and brothers [Sir-Petermann et al., 2002; Yildiz et al., 2003] and sons [Recabarren et al., 2008b] of PCOS women exhibit IR. The exact mechanism through which IR can affect spermatogenesis has yet to be discovered. A recent study by Calderón et al. [2016] examined the prevalence of male hypogonadism in moderate to severe obesity and its relationship with IR. It was found that free and total testosterone was negatively correlated with IR and low ejaculate volume with higher BMI and excess body weight.

Obesity-associated IR was demonstrated previously [Bloomgarden, 2003; Newgard et al., 2009; Takeno et al., 2016]. In PCOS women, weight loss and changing lifestyle prior to ovulation induction improved the live birth rate [Legro et al., 2016]. The adverse effect of obesity on semen quality and reproductive hormones was also demonstrated [Hakonsen et al., 2011; Jensen et al., 2004]. Obesity was found to be associated with poor semen quality and altered reproductive hormonal profile. A study on 483 male partners of infertile couples demonstrated that major differences in reproductive hormone levels are associated with increasing body weight, however, only extreme levels of obesity may negatively influence male reproductive potential [Chavarro et al., 2010]. Obesity was found to increase conversion of testosterone to oestradiol, leading to secondary hypogonadism through reproductive axis suppression [Michalakakis et al., 2013]. In another study obesity was also found to be associated with increased seminal insulin with concomitant reduced fertility parameters [Leisegang et al., 2014]. It was demonstrated that sons of PCOS women exhibit higher body weight from early infancy, and IR became evident as the subject got older. In this study, the BMI in

the unexplained infertility group was higher than the control group, but the difference was not significant. Therefore, the idiopathic infertility problem cannot be solely attributed to increased body fat; it has to be associated with IR.

It has been estimated that at least one abnormal lipid parameter is found in 70% of obese women with PCOS [Legro et al., 2001], which is most probably due to IR [Robinson et al., 1996]. Insulin and androgens levels in blood may have opposing effects on lipid profiles in PCOS patients [Li et al., 2016]. Brothers of women with PCOS have significantly higher total and LDL cholesterol as well as triglyceride levels, and IR [Sam et al., 2008]. In this study, serum total cholesterol was found to be significantly higher in the study group. HDL, LDL and triglyceride concentrations were comparable in both groups with no significant difference.

Although only men with normal hormonal profile were included, the FSH and LH levels were significantly higher in the study group compared with controls. Increased FSH and LH response to gonadotrophin-releasing hormone (GnRH) analogue [Liu et al., 2014], and elevated basal levels of FSH and LH with no decrease in testosterone were found in PCOS male relatives. This may be due to alteration in neuro-endocrine gonadotrophin secretion [Torchen et al., 2016]. In the current study, the total testosterone level was significantly lower in the study group. The cause of the lower testosterone and its relationship to the increased IR has yet to be investigated. It would be of interest to find out whether men with unexplained infertility and IR have first-degree women relatives with PCOS.

Conclusions

In conclusion, IR in men with unexplained infertility can be a possible cause of hypogonadism and idiopathic oligozoospermia as well as other metabolic abnormalities. More research is needed to further confirm this finding and to investigate the value of insulin sensitizing agents in the treatment of these cases of unexplained male factor infertility.

ARTICLE INFO

Article history:

Received 23 March 2017

Received in revised form 2 August 2017

Accepted 2 August 2017

Declaration: The authors report no financial or commercial conflicts of interest.

Keywords:

Dyslipidaemia

Insulin resistance

Male infertility

Oligozoospermia

REFERENCES

- Bloomgarden, Z., 2003. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. *Diabetes Care* 26, 1297–1303.
- Calderón, B., Gómez-Martín, J.M., Vega-Piñero, B., Martín-Hidalgo, A., Galindo, J., Luque-Ramírez, M., Escobar-Morreale, H.F., Botella-Carretero, J.I., 2016. Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. *Andrology* 4, 62–67.
- Cavallini, G., 2006. Male idiopathic oligoasthenoteratozoospermia. *Asian J. Androl.* 8, 143–157.
- Chavarro, J.E., Toth, T.L., Wright, D.L., Meeker, J.D., Hauser, R., 2010. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. *Fertil. Steril.* 93, 2222–2231.
- Colombo, J.B.I., Naz, R.K., 1999. Modulation of insulin-like growth factor-1 in the seminal plasma of infertile men. *J. Androl.* 20, 118–125.
- Day, F.R., Hinds, D.A., Tung, J.Y., Stolk, L., Styrkarsdottir, U., Saxena, R., Bjornes, A., Broer, L., Dunger, D.B., Halldorsson, B.V., Lawlor, D.A., Laval, G., Mathieson, I., McCardle, W.L., Louwers, Y., Meun, C., Ring, S., Scott, R.A., Sulem, P., Uitterlinden, A.G., Wareham, N.J., Thorsteinsdottir, U., Welt, C., Stefansson, K., Laven, J.S., Ong, K.K., Perry, J.R., 2015. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. *Nat. Commun.* 6, 8464.
- Diamanti-Kandarakis, E., Dunaif, A., 2012. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr. Rev.* 33, 981–1030.
- Filliponi, D., Feil, R., 2009. Perturbation of genomic imprinting in oligospermia. *Epigenetics* 4, 27–30.
- Friedrich, N., Thuesen, B., Jørgensen, T., Juul, A., Spielhagen, C., Wallaschofski, H., Linneberg, A., 2012. The association between IGF-I and insulin resistance: a general population study in Danish adults. *Diabetes Care* 35, 768–773.
- Goodarzi, M.O., Jones, M.R., Li, X., Chua, A.K., Garcia, O.A., Chen, Y.D., Krauss, R.M., Rotter, J.I., Ankener, W., Legro, R.S., Azziz, R., Strauss, J.F., 3rd, Dunaif, A., Urbanek, M., 2012. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. *J. Med. Genet.* 49, 90–95.
- Håkonsen, L.B., Thulstrup, A.M., Aggerholm, A.S., Olsen, J., Bonde, J.P., Andersen, C.Y., Bungum, M., Ernst, E.M., Hansen, M.L., Ernst, E.H., Ramlau-Hansen, C.H., 2011. Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men. *Reprod. Health* 8, 24.
- Hayes, M.G., Urbanek, M., Ehrmann, D.A., Armstrong, L.L., Lee, J.Y., Sisk, R., Karaderi, T., Barber, T.M., McCarthy, M.I., Franks, S., Lindgren, C.M., Welt, C.K., Diamanti-Kandarakis, E., Panidis, D., Goodarzi, M.O., Azziz, R., Zhang, Y., James, R.G., Olivier, M., Kissebah, A.H., Reproductive Medicine Network, Stener-Victorin, E., Legro, R.S., Dunaif, A., 2015. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotrophin secretion in European ancestry populations. *Nat. Commun.* 8, 7502.
- Jensen, T.K., Andersson, A.M., Jørgensen, N., Andersen, A.G., Carlsen, E., Petersen, J.H., Skakkebaek, N.E., 2004. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. *Fertil. Steril.* 82, 863–870.
- Katz, A., Nambi, S.S., Mather, K., Baron, A.D., Follmann, D.A., Sullivan, G., Quon, M.J., 2000. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J. Clin. Endocrinol. Metab.* 85, 2402–2410.
- Legro, R.S., Driscoll, D., Strauss, J.F., 3rd, Fox, J., Dunaif, A., 1998. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. *Proc. Natl. Acad. Sci. U.S.A.* 95, 14956–14960.
- Legro, R.S., Kunselman, A.R., Dunaif, A., 2001. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am. J. Med.* 111, 607–613.
- Legro, R.S., Kunselman, A.R., Demers, L., Wang, S.C., Bentley-Lewis, R., Dunaif, A., 2002. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 87, 2134–2138.
- Legro, R.S., Dodson, W.C., Kunselman, A.R., Stetter, C.M., Kris-Etherton, P.M., Williams, N.I., Gnatuk, C.L., Estes, S.J., Allison, K.C., Sarwer, D.B., Diamond, M.P., Schlaff, W.D., Casson, P.R., Christman, G.M., Barnhart, K.T., Bates, G.W., Usadi, R., Lucidi, S., Baker, V., Zhang, H., Eisenberg, E., Coutifaris, C., Dokras, A., 2016. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. *J. Clin. Endocrinol. Metab.* 101, 2658–2666.
- Leisegang, K., Bouic, P.J., Menkveld, R., Henkel, R.R., 2014. Obesity is associated with increased seminal insulin alongside reduced fertility parameters in a controlled male cohort. *Reprod. Biol. Endocrinol.* 12, 34.
- Li, S., Chu, Q., Ma, J., Sun, Y., Tao, T., Huang, R., Liao, Y., Yue, J., Zheng, J., Wang, L., Xue, X., Zhu, M., Kang, X., Yin, H., Liu, W., 2016. Discovery of novel lipid profiles in PCOS: do insulin and androgen oppositely regulate bioactive lipid production? *J. Clin. Endocrinol. Metab.* doi:10.1210/jc.2016-2692.
- Liu, D.M., Torchen, L.C., Sung, Y., Paparodis, R., Legro, R.S., Grebe, S.K., Singh, R.J., Taylor, R.L., Dunaif, A., 2014. Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndrome. *Hum. Reprod.* 29, 2764–2772.
- Mansour, R., Elfaissal, Y., Fahmy, I., Kamal, O., Serour, G., Aboulghar, M., 2013. Insulin resistance: a new diagnosis for the pathogenesis of idiopathic oligozoospermia and non-obstructive azoospermia. *Fertil. Steril.* 100 (3), S210.
- http://dx.doi.org/10.1016/j.fertnstert.2013.07.1323.
- Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28, 412–419.
- Michalakis, K., Mintziori, G., Kaprara, A., Tarlatzis, B.C., Goulis, D.G., 2013. The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. *Metabolism* 62, 457–478.
- Newgard, C.B., An, J., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Lien, L.F., Haqq, A.M., Shah, S.H., Arlotto, M., Slentz, C.A., Rochon, J., Galupp, D., Illkayeva, O., Wenner, B.R., Yancy, W.S., Jr., Eisonson, H., Musante, G., Surwit, R.S., Millington, D.S., Butler, M.D., Svetkey, L.P., 2009. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.* 9, 311–326.

- Nieschlag, E., Kamischke, A., 2010. Empirical therapies for idiopathic male infertility. In: Nieschlag, E., Behre, H.M., Nieschlag, S. (Eds.), *Andrology*, third ed. Springer-Verlag, Berlin Heidelberg, p. 457.
- Recabarren, S.E., Sir-Petermann, T., Rios, R., Maliqueo, M., Echiburú, B., Smith, R., Rojas- García, P., Recabarren, M., Rey, R.A., 2008a. Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood. *J. Clin. Endocrinol. Metab.* 93, 3318–3324.
- Recabarren, S.E., Smith, R., Rios, R., Maliqueo, M., Echiburú, B., Codner, E., Cassorla, F., Rojas, P., Sir-Petermann, T., 2008b. Metabolic profile in sons of women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 93, 1820–1826.
- Robinson, S., Henderson, A.D., Gelding, S.V., Kiddy, D., Niththyananthan, R., Bush, A., Richmond, W., Johnston, D.G., Franks, S., 1996. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. *Clin. Endocrinol. (Oxf)* 44, 277–284.
- Rosenfield, R.L., 1997. Current concepts of polycystic ovary syndrome. *Baillieres Clin. Obstet. Gynaecol.* 11, 307–333.
- Rosenfield, R.L., Ehrmann, D.A., 2016. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. *Endocr. Rev.* 37, 467–520.
- Sam, S., Coviello, A.D., Sung, Y.A., Legro, R.S., Dunaif, A., 2008. Metabolic phenotype in the brothers of women with polycystic ovary syndrome. *Diabetes Care* 31, 1237–1241.
- Sesti, G., Sciacqua, A., Cardellini, M., Marini, M.A., Maio, R., Vatrano, M., Succurro, E., Lauro, R., Federici, M., Perticone, F., 2005. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. *Diabetes Care* 28, 120–125.
- Shi, Y., Zhao, H., Shi, Y., Cao, Y., Yang, D., Li, Z., Zhang, B., Liang, X., Li, T., Chen, J., Shen, J., Zhao, J., You, L., Gao, X., Zhu, D., Zhao, X., Yan, Y., Qin, Y., Li, W., Yan, J., Wang, Q., Zhao, J., Geng, L., Ma, J., Zhao, Y., He, G., Zhang, A., Zou, S., Yang, A., Liu, J., Li, W., Li, B., Wan, C., Qin, Y., Shi, J., Yang, J., Jiang, H., Xu, J.E., Qi, X., Sun, Y., Zhang, Y., Hao, C., Ju, X., Zhao, D., Ren, C.E., Li, X., Zhang, W., Zhang, Y., Zhang, J., Wu, D., Zhang, C., He, L., Chen, Z.J., 2012. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. *Nat. Genet.* 44, 1020–1025.
- Sir-Petermann, T., Angel, B., Maliqueo, M., Carvajal, F., Santos, J.L., Pérez-Bravo, F., 2002. Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. *Diabetologia* 45, 959–964.
- Takeno, K., Tamura, Y., Kawaguchi, M., Takehi, S., Watanabe, T., Funayama, T., Furukawa, Y., Kaga, H., Yamamoto, R., Kim, M., Nishitani-Yokoyama, M., Shimada, K., Daida, H., Aoki, S., Taka, H., Fujimura, T., Sawada, S.S., Giacca, A., Kanazawa, A., Fujitani, Y., Kawamori, R., Watada, H., 2016. Relation between insulin sensitivity and metabolic abnormalities in Japanese men with BMI of 23–25 kg/m². *J. Clin. Endocrinol. Metab.* 101, 3676–3684.
- Torchen, L.C., Kumar, A., Kalra, B., Savjani, G., Sisk, R., Legro, R.S., Dunaif, A., 2016. Increased antimüllerian hormone levels and other reproductive endocrine changes in adult male relatives of women with polycystic ovary syndrome. *Fertil. Steril.* 106, 50–55.
- Verit, A., Verit, F.F., Oncel, H., Ciftci, H., 2014. Is there any effect of insulin resistance on male reproductive system? *Arch. Ital. Urol. Androl.* 86, 5–8.
- WHO, 2010. WHO Laboratory Manual for the Examination of Human Semen and Sperm-cervical Mucus Interaction, fifth ed. Cambridge University Press, Cambridge.
- Yildiz, B.O., Yarali, H., Oguz, H., Bayraktar, M., 2003. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 88, 2031–2036.